Matinas BioPharma gets NYSE American notice of noncompliance
On Aug. 31, 2026, Matinas BioPharma received a NYSE American notice of noncompliance with Section 1003(a)(i). The exchange cited stockholders’ equity of $1.8 million versus a $2.0 million minimum and losses in recent years.
On August 31, 2026, the company received notice from NYSE American that it is not in compliance with Section 1003(a)(i) because stockholders’ equity was $1.8 million, below the $2.0 million minimum, and it reported losses in recent years.
The exchange had previously notified the company of noncompl…